Clinical Publications |
Scientific Publications |
May 2023 |
Treatment after failure of frontline therapy of chronic myeloid leukemia in chronic phase including allogeneic hematopoietic stem cell transplant - Review Uhm J. Blood Res, April 2023 - open access publication |
Frequency and driver mutation diversity in concomitant chronic myeloid leukemia and Philadelphia chromosome-negative myeloproliferative neoplasm Langabeer SE et al. Int J Hematol, April 2023 (epub ahead of print) |
Developing therapeutic approaches for CML: a review Kumar V et al. Mol Cell Biochem, May 2023 |
Differentiation of imatinib-resistant chronic myeloid leukemia cells with BCR-ABL-T315I mutation induced by Jiyuan Oridonin A. Xu Y et al. Cancer, May 2023 – open access publication |
The EMA assessment of Asciminib for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who were previously treated with at least two tyrosine kinase inhibitors Tesileanu CMS et al. Oncologist, May 2023 (epub ahead of print) – open access publication |
I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition Gao C et al. Front Pharmacol, April 2023 – open access publication |
Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase focusing on age and dose effects Tokuhira M et al. Int J Hematol, May 2023 (epub ahead of print) |
Inhibition of casein kinase 2 induces cell death in tyrosine kinase inhibitor resistant chronic myelogenous leukemia cells Mitrovsky O et al. PLoSOne, May 2023 – open access publication
|
Impact of obesity surgery on tyrosine kinase inhibitor responses and survival outcomes in patients with chronic myeloid leukemia: Further data are still warranted! Eskazan AE et al. Cancer, May 2023 (epub ahead of print) |
|
JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response Tossoni L et al. Ann Hematol, May 2023 |
|
April 2023 |
The outcome of post-transplant asciminib in patients with CML Fernando F et al. Bone Marrow Transplant, April 2023 (epub ahead of print) |
New patterns of genetic instability in chronic myelogenous leukemia: interesting, but not ready for clinical use Schiffer CA. Haematologica, April 2023 (epub ahead of print) – open access publion |
Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial Réa D et al. Leukemia, April 2023 (epub ahead of print) – open access publication |
The structure of the hematopoietic system can explain chronic myeloid leukemia progression Pérez-Jiménez M et al. Sci Rep, April 2023 – open access publication |
Management of chronic myeloid leukemia in 2023 – Common ground and common sense - Review Senapati J et al. Blood Cancer J, April 2023 – open access publication |
Characterization of bone marrow niche in chronic myeloid leukemia patients identifies CXCL14 as a new therapeutic option Polinska M et al. Blood, April 2023 (epub ahead of print) |
Efficacy and safety of nilotinib in chronic myeloid leukemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study Dulucq S et al. Br J Haematol, April 2023 (epub ahead of print) – open access publication |
IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia Fiordi B et al. Haematologica, April 2023 (epub ahead of print) – open access publication |
Clonal hematopoiesis onset in chronic myeloid leukemia patients developing an adverse cardiovascular event Tarantini F et al. Leuk Res, April 2023 |
Molecular subtypes predict therapeutic responses and identifying and validating diagnostic signatures based on machine learning in chronic myeloid leukemia Zhong FM et al. Cancer Cell Int, April 2023 – open access publication |
Managing women of childbearing age with chronic myeloid leukemia: Safety and treatment considerations Expert Rev Hematol, April 2023 (epub ahead of print) |
Molecular subtypes predict therapeutic responses and identifying and validating diagnostic signatures based on machine learning in chronic myeloid leukemia Zhong FM et al. Cancer Cell Int, April 2023 – open access publication |
An analysis of dasatinib treatment patterns in patients with chronic myeloid leukemia after experiencing pleural effusion during dasatinib therapy McBride A et al. Acta Haematol, April 2023 (epub ahead of print) |
|
Efficacy and safety of nilotinib as frontline therapy in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials Luciano L et al. Ann Hematol, April 2023 (epub ahead of print) – open access publication |
|
Applications of machine learning in chronic myeloid leukemia - Review Elhadary M et al. Diagnostics(Basel), April 2023 – open access publication |
|
Breaking the mold: asciminib as a standard of care of the therapeutic armamentarium of chronic myeloid leukemia in the upfront setting Yilmaz R et al. Future Oncol, April 2023 (epub ahead of print) |
|
Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia – Review Han JJ et al. Blood Res, April 2023 (epub ahead of print) – open access publication |
|
Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings - Review Cheng F et al. Front Oncol, April 2023 – open access publication |
|
Assessment of imatinib as a primary treatment of chronic myeloid leukemia in chronic phase: a Cohort Study Merin D et al. J Oncol Pharm Pract, April 2023 |
|
March 2023 |
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL Hochhaus A et al. Leukemia, March 2023 – open access publication |
AMPK inhibition induces MCL1 mRNA destabilization via the p38 MAPK/miR-22/HuR axis in chronic myeloid leukemia cells Lee YC et al. Biochem Pharmacol, March 2023 |
Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results Mauro MJ et al. Leukemia, March 2023 (epub ahead of print) – open access publication |
The interplay between telomeric complex members and BCR::ABL1 oncogenic tyrosine kinase in the maintenance of telomere lengths in chronic myeloid leukemia Deregowska A et al. J Cancer Res Clin Oncol, March 2023 (epub ahead of print) – open access publication |
Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention Shanmunagathan N et al. Haematologica, March 2023 (epub ahead of print) – open access publication |
Induction of DNMT1-dependent demethylation of SHP-1 by the natural flavonoid compound Baicalein overcame imatinib-resistance in CML CD34+ cells Xu X et al. Cell Commun Signal, March 2023 – open access publication |
Editorial: Advances in the treatment of chronic myeloid leukemia Eskazan AE et al. Front Oncol, March 2023 – open access publication |
Imatinib blocks tyrosine phosphorylation of Smad4 and restores TFG-ß growth-suppressive signaling in BCR-ABL1-positive leukemia Wang L et al. Signal Transduct Target Ther, March 2023 – open access publication |
High-risk additional cytogenetic aberrations in a Dutch chronic phase chronic myeloid leukemia patient population Kockerols CCB et al. Haematologica, March 2023 (epub ahead of print) – open access publication |
The prognostic and therapeutic potential of HO-1 in leukemia and MDS – Review Sadeghi M et al. Cell Commun Signal, March 2023 – open access publication |
Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence Shallis RM et al. Blood Adv, March 2023 (epub ahead of print) – open access publication |
NOX2 and NOX4 control mitochondrial function in chronic myeloid leukemia Romo-González M et al. Free Radic Biol Med, March 2023 – open access publication |
The economic burden of chronic myeloid leukemia in patients with later lines: Findings from a real-world analysis in Italy Breccia M et al. Adv Ther, March 2023 – open access publication |
TSPAN32 suppresses chronic myeloid leukemia pathogenesis and progression by stabilizing PTEN Qiu Q et al. Signal Transduct Target Ther, March 2023 – open access publication |
A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia Krishnan V et al. Blood, March 2023 (epub ahead of print) |
Molecular mechanisms of tyrosine kinase inhibitor resistance in chronic myeloid leukemia Kaehler M and Cascorti I. Handb Exp Pharmacol, March 2023 (epub ahead of print) |
Effectiveness and management of ponatinib as second-line treatment in chronic myeloid leukemia: an analysis from the monitoring registries of the Italian Medicines Agency (AIFA) Breccia M et al. Ann Hematol, March 2023 (epub ahead of print) |
|
Current CML guidelines overemphasize second generation TKIs: revisiting the paradigm Walia A and Prasad V. Blood Cancer J, March 2023 – open access publication |
|
Eltrombopag for tyrosine kinase inhibitors-associated thrombocytopenia in chronic myeloid leukemia Aleem A et al. Int J Hematol, March 2023 (epub ahead of print) |
|
Association between bariatric surgery and outcomes in chronic myeloid leukemia Haddad FG et al. Cancer, March 2023 (epub ahead of print) |
|
Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase – Review Choi EJ. Blood Res, March 2023 (epub ahead of print) – open access publication |
|
Patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia (RODEO study): study protocol for prospective, multicentre, single-arm trial Djodikromo MF et a. BMC Cancer, March 2023 – open access publication |
|
February 2023 |
Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells Tsubaki M et al. BMB Rep, February 2023 – open access publication
|
Tyrosine kinase inhibitors combined with venetoclax and azacytidine as an effective therapy for the novo lymphoid blast phase-chronic myeloid leukemia Yang Z et al. Leuk Res, February 2023 (epub ahead of print) |
Repurposing the Bis-Biguanide Alexidine in combination with tyrosine kinase inhibitors to eliminate leukemic stem/progenitor cells in chronic myeloid leukemia Muselli F et al. Cancers(Basel), February 2023 – open access publication |
Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: characteristics, potential mechanism, and clinical management strategies – Review Cheng F et al. Front Oncol, February 2023 – open access publication |
Discovery of CZS-241: A potent, selective, and orally available Polo-like kinase 4 inhibitor for the treatment of CML Sun Y et al. J Med Chem, February 2023
|
Cardiovascular toxicities associated with tyrosine kinase inhibitors - Review Sahegh N et al. Curr Cardiol Rep, February 2023 (epub ahead of print) |
Pharmacokinetics of single- and multiple-dose flumatinib in patients with chronic phase chronic myeloid leukemia Jiang B et al. Front Oncol, February 2023 – open access publication |
The bone marrow immune environment in CML: Treatment responses, treatment-free remission and therapeutic vulnerabilities Patterson SD & Copland M. Curr Hematol Malig Rep, February 2023 (epub ahead of print) – open access publication |
A survey of patient experience in CML: American and Canadian Perspectives Hillis C et al. Patient Prefer Adherence, February 2023 – open access publication |
|
Importance of tyrosine kinase inhibitor treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-Free study Yoshida C et al. Int J Hematol, February 2023 (epub ahead of print) – open access publication |
|
Five-year cardiovascular outcomes in patients with chronic myeloid leukemia treated with imatinib, dasatinib, or nilotinib: A cohort study using data from a large multinational collaborative network Nunes RAB et al. Front Cardiovasc Med, February 2023 – open access publication |
|
Cognition in patients treated with targeted therapy for chronic myeloid leukemia: a controlled comparison Hyland KA et al. Leuk Lymphoma, February 2023 |
|
Family planning and pregnancy in patients with chronic myeloid leukemia – Review Berman E et al. Curr Hematol Malig Rep, February 2023 (epub ahead of print) |
|
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modelling and pathway analysis Radich JP et al. Haematologica, February 2023 (epub ahead of print) – open access publication |
|
January 2023 |
Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in CML Irani YD et al. Blood Adv, January 2023 (epub ahead of print) – open access publication |
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL Hochhaus A et a. Leukemia, January 2023 (epub ahead of print) – open access publication |
RHOA-regulated IGFBP2 promotes invasion and drives progression of BCR-ABL1 chronic myeloid leukemia Zhang H et al. Haematologica, January 2023 – open access publication |
Matching adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors Atallah E et al. J Caner Res Clin Oncol, January 2023 (epub ahead of print) – open access publication |
Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib Häselbarth L et al. Cancer Immunol Immunother, January 2023 (epub ahead of print) – open access publication |
Allogeneic transplantation for chronic myeloid leukemia: I’m not dead yet! Radich J. Am J Hematol, January 2023 – open access publication |
mTORC2 is activated under hypoxia and could support chronic myeloid leukemia stem cells Panuzzo C et al. Int J Mol Sci, January 2023 – open access publication |
Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor Bidikian A et al. Am J Hematol (epub ahead of print) |
BH3 mimetics and TKI combined therapy for CML Brumatti G et al. Biochem, January 2023 – open access publication |
The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors Jabbour EJ et al. Am J Hematol, January 2023 (epub ahead of print) |
Differential inhibition of T cell receptor and STAT5 signalling pathways determine the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia Harrington P et al. Haematologica, January 2023 (epub ahead of print) – open access publication |
A systematic review on second treatment-free remission (TFR) attempt in chronic myeloid leukemia (CML): Can it be applied in clinical practice? - Review Çiftçiler R et al. Clin Lymphoma Myeloma Leuk (epub ahead of print) |
|
Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic-phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring Bataller A et al. Leuk Lymphoma, January 2023 (epub ahead of print) |
|
Is it time to reconsider molecular response milestones in CML? Walia A and Prasad V. Am J Hematol, January 2023 (epub ahead of print) |